Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 2
2012 2
2013 5
2014 4
2015 7
2016 10
2017 10
2018 7
2019 5
2020 18
2021 16
2022 15
2023 11
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes.
Sallman DA, DeZern AE, Garcia-Manero G, Steensma DP, Roboz GJ, Sekeres MA, Cluzeau T, Sweet KL, McLemore A, McGraw KL, Puskas J, Zhang L, Yao J, Mo Q, Nardelli L, Al Ali NH, Padron E, Korbel G, Attar EC, Kantarjian HM, Lancet JE, Fenaux P, List AF, Komrokji RS. Sallman DA, et al. Among authors: al ali nh. J Clin Oncol. 2021 May 10;39(14):1584-1594. doi: 10.1200/JCO.20.02341. Epub 2021 Jan 15. J Clin Oncol. 2021. PMID: 33449813 Free PMC article. Clinical Trial.
Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML).
Gurney M, Mangaonkar AA, Lasho T, Finke C, Al-Kali A, Gangat N, Shah MV, Alkhateeb HB, Tefferi A, Sallman D, Xie Z, Viswanatha D, Reichard K, Al Ali N, Komrokji R, Padron E, Patnaik MM. Gurney M, et al. Among authors: al ali n. Leukemia. 2023 Aug;37(8):1753-1756. doi: 10.1038/s41375-023-01964-3. Epub 2023 Jul 8. Leukemia. 2023. PMID: 37422593 No abstract available.
SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity.
Mangaonkar AA, Lasho TL, Finke C, Ketterling RP, Reichard KK, McCullough K, Gangat N, Al-Kali A, Begna KH, Hogan WH, Litzow MR, Alkhateeb H, Shah M, Pardanani A, Tefferi A, Al Ali NH, Talati C, Sallman D, Padron E, Komrokji R, Patnaik MM. Mangaonkar AA, et al. Among authors: al ali nh. Haematologica. 2022 May 1;107(5):1189-1192. doi: 10.3324/haematol.2021.280463. Haematologica. 2022. PMID: 35142154 Free PMC article. No abstract available.
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.
Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek S. Bose P, et al. Among authors: al ali n. Blood. 2018 Nov 8;132(19):2100-2103. doi: 10.1182/blood-2018-05-848473. Epub 2018 Sep 21. Blood. 2018. PMID: 30242087 Free PMC article. No abstract available.
Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.
Melody M, Al Ali N, Zhang L, Ramadan H, Padron E, Sallman D, Sweet K, Lancet J, List A, Bennett JM, Komrokji R. Melody M, et al. Among authors: al ali n. Clin Lymphoma Myeloma Leuk. 2020 May;20(5):324-328. doi: 10.1016/j.clml.2020.01.003. Epub 2020 Jan 14. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32044274 Clinical Trial.
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative Neoplasms.
Castillo Tokumori F, Al Ali N, Chan O, Sallman D, Yun S, Sweet K, Padron E, Lancet J, Komrokji R, Kuykendall AT. Castillo Tokumori F, et al. Among authors: al ali n. Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):e521-e525. doi: 10.1016/j.clml.2022.01.015. Epub 2022 Feb 3. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35241387 Free PMC article.
Autoimmune diseases and myelodysplastic syndromes.
Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK. Komrokji RS, et al. Among authors: al ali nh. Am J Hematol. 2016 May;91(5):E280-3. doi: 10.1002/ajh.24333. Epub 2016 Apr 4. Am J Hematol. 2016. PMID: 26875020 Free article.
Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.
Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, Kuykendall A, Chan O, Sweet K, Lancet JE, Padron E, Sallman DA, Komrokji R. Jain AG, et al. Among authors: al ali n. Haematologica. 2024 Feb 1. doi: 10.3324/haematol.2023.283661. Online ahead of print. Haematologica. 2024. PMID: 38299605 Free article.
103 results